Table 2 Baseline demographics
| Â | High ADI | Low ADI | P value |
|---|---|---|---|
Number of patients | 6 | 12 | Â |
Age at diagnosis of viral retinitis, mean (SD) | 38.0 (5.5) | 51.3 (15.2) | 0.06 |
Sex | |||
 Male | 0 (0%) | 6 (50%) | 0.03 |
 Female | 6 (100%) | 6 (50%) |  |
Race | |||
 White | 1 (17%) | 5 (42%) | 0.27 |
 Black | 5 (83%) | 5 (42%) |  |
 Not reported | 0 (0%) | 2 (17%) |  |
Insurance type | |||
 Private | 0 (0%) | 7 (58%) | 0.07 |
 Public | 3 (50%) | 2 (17%) |  |
 Medicare | 3 (50%) | 2 (17%) |  |
 No insurance | 0 (0%) | 1 (8%) |  |
Lost to follow-up | 1 (17%) | 4 (33%) | 1.00 |
Missed appointments, median (IQR) | 11.0 (7.8, 13.3) | 0.0 (0.0, 1.8) | 0.009 |
Missed appointments due to transportation issues | 5 (83%) | 4 (33%) | 0.13 |
Bilateral viral retinitis | 5 (83%) | 6 (50%) | 0.32 |
Bilateral viral retinitis-associated RD | 3 (50%) | 3 (25%) | 0.34 |
Cause of immune dysfunction | Â | Â | Â |
 Medications | 0 (0%) | 1 (8%) | 0.96 |
 Malignancy  Chronic Lymphocytic Leukemia | 0 (0%) | 1 (8%) |  |
  Non-Hodgkin’s Lymphoma | 0 (0%) | 1 (8%) |  |
 HIV | 5 (83%) | 4 (33%) |  |
 Systemic Disorder  Myelodysplastic syndrome | 0 (0%) | 1 (8%) |  |
  Sarcoidosis | 0 (0%) | 1 (8%) |  |
 None | 1 (17%) | 3 (25%) |  |
Patients with HIV | 5 (83%) | 4 (33%) | 0.13 |
Causative virus | |||
 HSV | 0 (0%) | 4 (33%) | 0.31 |
 VZV | 1 (17%) | 1 (8%) |  |
 CMV | 5 (83%) | 7 (58%) |  |
Area of viral retinitis (DAs), mean (SD) | 17.6 (11.8) | 17.5 (13.5) | 0.99 |